Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SPR | P35270 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5775155 | 1.00 | SIGMAR1 (0.47) | SIGMAR1CNR2LTA4HMAPTSPR | |
| SCHEMBL1009164 | 0.88 | LTA4H (0.44) | SIGMAR1CNR2LTA4H | |
| SCHEMBL18711752 | 0.88 | LTA4H (0.53) | SIGMAR1CNR2LTA4HMAPTSPR | |
| SCHEMBL12356590 | 0.88 | LTA4H (0.53) | SIGMAR1CNR2LTA4HMAPTSPR | |
| SCHEMBL21929952 | 0.88 | FAAH (0.42) | SIGMAR1CNR2HDAC1CHRM3 | |
| SCHEMBL19281766 | 0.88 | FAAH (0.42) | SIGMAR1CNR2HDAC1CHRM3 | |
| SCHEMBL29937379 | 0.88 | SIGMAR1 (0.50) | SIGMAR1 | |
| SCHEMBL3056649 | 0.87 | LTA4H (0.43) | CNR2LTA4HSPR | |
| SCHEMBL11778646 | 0.85 | USP2 (0.47) | SIGMAR1CNR2LTA4HMAPTSPR | |
| SCHEMBL5591401 | 0.84 | GAA (0.45) | LTA4HHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275048-A1 | Substituted Diazabicycloalkane Derivates | ABBOTT LABORATORIES (US) | 2008-11-06 | — | — | US | disclosed |
| EP-1359152-B1 | Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands | ABBOTT LAB (US) | 2008-05-07 | — | — | EP | disclosed |
| US-7265115-B2 | Diazabicyclic CNS active agents | ABBOTT LABORATORIES (US) | 2007-09-04 | — | — | US | disclosed |
| US-20030225268-A1 | Diazabicyclic CNS active agents | ABBVIE INC. | 2003-12-04 | — | — | US | disclosed |
| EP-1147112-B1 | DIAZABICYCLIC DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | ABBOTT LAB (US) | 2003-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275048-A1 | Substituted Diazabicycloalkane Derivates | CHRNA7, CHRNA1, CHRNA2 | SIGMAR1 420/4885CNR2 46/4885LTA4H 1680/4885 |
| US-20030225268-A1 | Diazabicyclic CNS active agents | GABRE, GRIN1, CNTN1 | SIGMAR1 549/4885CNR2 283/4885LTA4H 2042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.